DexCom Inc. (DXCM) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
DexCom Inc. (DXCM) advanced +1.67% to $79.93 as options desks priced 54% call premium vs. 46% put protection around the $78 max-pain magnet. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support.
Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 11.2% year on year to $1.34 billion. The company expects the full year’s revenue to be around $5.
DexCom has enjoyed a strong run over the past year, yet the share price still leaves a basic question on the table for investors who care about cash flows. With the stock now trading around US$82.29, the issue is whether
DexCom (NasdaqGS:DXCM) has launched its Dexcom G7 15 Day Continuous Glucose Monitoring System in Canada, following Health Canada authorization. The Dexcom G7 15 Day is described as the longest duration CGM system current
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.
JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the price target from $82 to $85.
S&P 500 unusual-volume screen for Oct. 30, 2026: Reddit fell 30.15% on heavy volume, Global Payments rose 10.41%, and several other stocks traded above average.
DexCom (DXCM) posted better-than-expected Q3 results and raised its 2026 revenue guidance, and US sh
Record patient starts and type 2 diabetes share gains fuel 11% revenue growth.
Dexcom, known for its G-series of diabetes wearables, topped September-quarter expectations late Thursday, leading to a guidance hike.
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →
Why DXCM Stock advanced +1.67% Today — RQD Quant Desk Flash. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support.